Table 2.

Clinical evaluation of triptolide derivatives

Derivatives	Disease	Dosage regimen	Safety	Status	References
PG490-88	Advanced solid tumors	0.5–18 mg/m2, infusion for 2 times every 3 weeks (days 1 and 8)	Anaemia, fatigue, nausea, vomiting, diarrhoea and constipation; two cases of death at the dose of 12 and 18 mg/m2	Phase I: suspended	[116]
	Refractory or relapsing acute leukemia	0.15–13 mg/m2, infusion for 5 consecutive days every 15 days	Dose-limited cerebellar toxicity	Phase I: completed	[128]
LLDT-8	Rheumatoid arthritis	0.25–1.0 mg/day, 24 weeks	Reversible leukopenia, hematologic toxicity, and upper respiratory tract infection	Phase II: completed	[129]
	HIV-associated chronic immune activation	N/A	N/A	Phase I: ongoing	[113]
Minnelide	Pancreatic cancer	0.67 mg/m2, infusion for 21 consecutive days every 28 days	Reversible leukopenia, neutropenia, and cerebellar toxicities	Phase II: completed	[130]
	Advanced solid tumors	Minnelide™ Capsules, oral administration for 21 consecutive days every 28 days	N/A	Phase I: ongoing	[131]